Wire · opportunities
Exelixis (EXEL) Gets Longer FDA Review As Cancer Pipeline Milestone Advances
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 September 2026 · Fusion42 review
Exelixis received an extended FDA review for its zanzalintinib drug in metastatic colorectal cancer due to new safety and efficacy data, delaying the approval decision to March 2027. The company also reached a milestone payment with Adagene in its antibody drug conjugate program, reflecting ongoing pipeline diversification beyond its current main product, cabozantinib.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a longer wait for FDA approval on a key colorectal cancer drug, shifting your launch timing and cash flow expectations. The milestone from Adagene signals pipeline progress but puts you against established biologics players, raising pressure to prove your next-gen cancer treatments.
◆ Coverage
1 source · 12 Sep 2026
◆ Related on Wire
◆ Topics